Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
Senseonics (NASDAQ: SENS) reported Q4 2025 revenue of $14.3M (up ~72% YoY) and full year 2025 revenue of $35.3M (up ~57% YoY). The company received CE Mark for Eversense 365, launched U.S. AID integration with twiist, secured an IDE for the Gemini pivotal trial and began enrollment.
Cash and investments stood at $94.3M with $35.3M debt. Senseonics expects 2026 revenue of $58–$62M and ~50% gross margin, reflecting commercialization transition and DTC marketing investments.
Positive
- Full-year revenue +57% YoY to $35.3M
- Q4 revenue +72% YoY to $14.3M
- CE Mark approval for Eversense 365 in EU
- IDE approval and first enrollments for Gemini pivotal trial
- 2026 guidance $58–$62M revenue and ~50% gross margins
- U.S. new patient growth +103% in 2025
Negative
- Selling, general & administrative +$18.3M year-over-year for 2025
- Net loss $69.1M for 2025, indicating continued unprofitability
- Outstanding indebtedness $35.3M as of December 31, 2025
Market Reaction – SENS
Following this news, SENS has declined 6.72%, reflecting a notable negative market reaction. Argus tracked a trough of -5.4% from its starting point during tracking. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $7.64. This price movement has removed approximately $22M from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Sector peers like BFLY (-18.32%), PACB (-3.17%) and others are down, while the momentum scanner flags SENS as moving up, suggesting stock-specific dynamics rather than a broad medical device move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 earnings | Positive | -7.6% | Revenue up 90% YoY and return to positive gross profit. |
| Aug 06 | Q2 2025 earnings | Positive | -4.9% | 37% revenue growth and $77.8M capital raised. |
| May 08 | Q1 2025 earnings | Positive | -15.2% | 24% revenue growth with improved gross profit and lower loss. |
| Mar 03 | FY 2024 results | Positive | -19.3% | Launch of Eversense 365 and 56% patient base growth. |
| Nov 07 | Q3 2024 earnings | Positive | -12.5% | FDA approval of Eversense 365 despite lower quarterly revenue. |
Earnings releases with revenue growth and guidance have historically been followed by negative price reactions, indicating a pattern of sell-offs on earnings.
Recent earnings reports from Nov 2024 through Nov 2025 show steady revenue growth and improving gross profit for Senseonics, supported by launches and approvals for the Eversense 365 CGM and guidance pointing to higher annual revenue. Despite these operational gains and corporate actions like a 1-for-20 reverse split and listing transition, shares consistently moved lower after earnings, underscoring a history of negative post-earnings reactions even on seemingly constructive updates.
Historical Comparison
Over the last 5 earnings-related releases, SENS moved an average of -11.89%, often declining despite reporting revenue growth, improving margins and constructive guidance.
Earnings updates show revenue rising from $4.3M in Q3 2024 to $8.1M in Q3 2025, improving gross profit, and guidance stepping up toward mid‑$30M annual revenue alongside strategic actions like a reverse split and uplisting plans.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Aug 06, 2025 allows Senseonics to issue up to $300 million in securities, including a $100 million ATM program, providing capital-raising flexibility but also potential dilution for shareholders.
Market Pulse Summary
The stock is down -6.7% following this news. A negative reaction despite strong top-line growth fits the historical pattern: past earnings events produced an average move of -11.89% even as revenue expanded. Q4 2025 revenue of $14.3M and 2025 revenue of $35.3M mark sizable gains, but the company still posted a $69.1M annual net loss and expects heavy 2026 investment. The existing $300M shelf registration and elevated operating costs may reinforce market focus on dilution and profitability risks.
Key Terms
continuous glucose monitoring (CGM) medical
CE Mark regulatory
Investigational Device Exemption (IDE) regulatory
pivotal trial medical
Automated Insulin Delivery (AID) System medical
AI-generated analysis. Not financial advice.
Generated Q4 revenue of
Received CE Mark approval for commercialization of Eversense 365 in Europe
Launched first Eversense 365 AID system integration, with twiist in the US
GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update.
Recent Highlights & Accomplishments
- Generated fourth quarter 2025 revenue of
$14.3 million , an increase of approximately72% year-over-year, and full year 2025 revenue of$35.3 million , an increase of approximately57% year-over-year - Achieved
103% new patient growth in the U.S. in 2025 versus 2024, driven largely by positive returns from direct-to-consumer (DTC) marketing efforts - Further development of the Eon Care inserter network to 60 providers performing approximately
24% of all U.S. insertions in 2025 - Continued growth of the HCP channel, with the number of active prescribers growing over
80% from 2024 to 2025 - Received CE Mark approval for Eversense 365 in the European Union (EU)
- Secured Investigational Device Exemption (IDE) approval from the FDA to commence a pivotal trial for the self-powered battery enabled Gemini sensor and enrolled the first patients in the trial, which the Company expects to complete in the second half of 2026
- Launched the combination of the twiist™ Automated Insulin Delivery (AID) System integrated with the Eversense® 365 CGM system across the U.S.
- Executed agreements with Ascensia Diabetes Care to take back commercialization and distribution of Eversense beginning January 1, 2026
Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics said, “In 2025, we took strategic actions to set the Company up for long term growth. Successfully bringing commercial operations in-house and investing heavily in DTC marketing, we built the foundations necessary to achieve the full potential of the world’s first and only year-long CGM. We delivered encouraging commercial results last year, and expect this momentum to continue. In 2026 we plan to expand Eversense 365 compatibility with AID systems, launch in Europe and complete the Gemini pivotal trial, an important milestone for our exciting innovation pipeline. These efforts, coupled with improved margins, set Senseonics up for continued strong performance this year and beyond. We expect these efforts, coupled with improved margins, will set Senseonics up for continued strong performance this year and beyond.”
Fourth Quarter 2025 Results:
Total revenue for the fourth quarter of 2025 was
Fourth quarter 2025 gross profit was
Fourth quarter 2025 research and development expenses decreased by
Fourth quarter 2025 selling, general and administrative expenses increased by
Net loss was
Full Year 2025 Results:
Total revenue for 2025 was
Gross profit for 2025 was
Research and development expenses for 2025 decreased by
Selling, general and administrative expenses for 2025 increased by
Net loss was
Cash, cash equivalents and investments were
Full Year 2026 Financial Outlook
Senseonics expects full-year 2026 global net revenue to be approximately
Conference Call Information
Management will hold a conference call to review the Company’s fourth quarter and full year 2025 performance starting today at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics’ website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-343-5172 (US/Canada) or 1-203-518-9856 (International), passcode SENSQ4, approximately five to ten minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Senseonics, including the revenue and gross margin projections under the heading “Full Year 2026 Financial Outlook,” statements regarding the ongoing transition of Eversense commercial operations from Ascensia, the commercial launch of Eversense 365 in the European Union, the expanded compatibility of Eversense 365 with automated insulin delivery systems, the anticipated timing of the completion of the Gemini trial, the future demand for Eversense, and other statements containing the words "believe," “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks and uncertainties related to the transition of commercial responsibility for Eversense from Ascensia, including the negotiation, finalization and execution of the local purchase agreements related to the Eversense commercial operations in the European Union; uncertainties in insurer, regulatory and administrative processes and decisions; uncertainties in the development and registration and roll-out of new technology and solutions; uncertainties in finalizing integration and commercial terms and coordination with health systems and other new collaboration partners and third parties; uncertainties inherent in the ongoing commercialization and expansion of the Eversense product and Senseonics’ and its partners’ activities; uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs; and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2025 and quarterly reports on Form 10-Q filed with the SEC under the heading "Risk Factors." The forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
| Senseonics Holdings, Inc. Unaudited Consolidated Balance Sheets (in thousands, except for share and per share data) | ||||||||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 40,234 | $ | 74,597 | ||||
| Restricted cash | 315 | 315 | ||||||
| Short term investments, net | 53,796 | — | ||||||
| Accounts receivable, net | 6,807 | 1,365 | ||||||
| Accounts receivable, net - related parties | 5,312 | 4,921 | ||||||
| Inventory, net | 6,703 | 4,421 | ||||||
| Prepaid expenses and other current assets | 4,366 | 5,819 | ||||||
| Total current assets | 117,533 | 91,438 | ||||||
| Deposits and other assets | 4,536 | 4,926 | ||||||
| Property, equipment and intangible assets, net | 4,200 | 4,074 | ||||||
| Total assets | $ | 126,269 | $ | 100,438 | ||||
| Liabilities and Stockholders’ (Deficit) Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,059 | $ | 3,205 | ||||
| Accrued expenses and other current liabilities | 15,091 | 13,636 | ||||||
| Accrued expenses and other current liabilities, related parties | 5,198 | 1,870 | ||||||
| Note payable, current portion, net | — | 20,138 | ||||||
| Total current liabilities | 24,348 | 38,849 | ||||||
| Long-term debt and notes payables, net | 35,586 | 34,703 | ||||||
| Non-current operating lease liabilities | 5,289 | 5,785 | ||||||
| Total liabilities | 65,223 | 79,337 | ||||||
| Commitments and contingencies | ||||||||
| Preferred stock and additional paid-in-capital, subject to possible redemption: | — | 37,656 | ||||||
| Total temporary equity | — | 37,656 | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Common stock, | 41 | 30 | ||||||
| Additional paid-in capital | 1,077,923 | 931,289 | ||||||
| Accumulated other comprehensive income | 69 | — | ||||||
| Accumulated deficit | (1,016,987 | ) | (947,874 | ) | ||||
| Total stockholders' equity (deficit) | 61,046 | (16,555 | ) | |||||
| Total liabilities, temporary equity and stockholders’ equity (deficit) | $ | 126,269 | $ | 100,438 | ||||
| Senseonics Holdings, Inc. Unaudited Consolidated Statements of Operations and Comprehensive Loss (in thousands, except for share and per share data) | ||||||||
| Years Ended | ||||||||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenue, net | $ | 17,084 | $ | 3,973 | ||||
| Revenue, net - related parties | 18,173 | 18,499 | ||||||
| Total revenue | 35,257 | 22,472 | ||||||
| Cost of sales | 19,494 | 21,939 | ||||||
| Gross profit | 15,763 | 533 | ||||||
| Expenses: | ||||||||
| Research and development expenses | 31,592 | 41,144 | ||||||
| Selling, general and administrative expenses | 52,508 | 34,231 | ||||||
| Operating loss | (68,337 | ) | (74,842 | ) | ||||
| Other income (expense), net: | ||||||||
| Interest income | 4,198 | 4,502 | ||||||
| Interest expense | (4,951 | ) | (8,437 | ) | ||||
| Gain on change in fair value of derivatives | — | 102 | ||||||
| Other expense ( income) | (23 | ) | 59 | |||||
| Total other expense, net | (776 | ) | (3,774 | ) | ||||
| Net Loss | (69,113 | ) | (78,616 | ) | ||||
| Other comprehensive income | ||||||||
| Unrealized gain on marketable securities | 69 | 11 | ||||||
| Total other comprehensive income | 69 | 11 | ||||||
| Total comprehensive loss | $ | (69,044 | ) | $ | (78,605 | ) | ||
| Basic net loss per common share | $ | (1.66 | ) | $ | (2.50 | ) | ||
| Basic weighted-average shares outstanding | 41,727,983 | 31,486,079 | ||||||
| Diluted net loss per common share | $ | (1.66 | ) | $ | (2.50 | ) | ||
| Diluted weighted-average shares outstanding | 41,727,983 | 31,486,079 | ||||||
FAQ
What were Senseonics (SENS) Q4 2025 and full-year 2025 revenue results?
What does the CE Mark for Eversense 365 mean for SENS and European commercialization?
What is Senseonics' full-year 2026 financial guidance and growth expectations (SENS)?
What is the status and timeline of the Gemini pivotal trial for Senseonics (SENS)?
How does Senseonics taking back Eversense commercialization from Ascensia affect shareholders (SENS)?
